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Abstract: Progranulin is a widely expressed protein that is involved in the regulation of multiple biological processes, 
including embryogenesis, host defense, and wound repair. In the central nervous system, progranulin is constitutively 
expressed at modest levels in neurons and microglia, but shows dramatic microglial immunoreactivity in degenerative 
diseases that exhibit prominent neuroinflammation. In addition to the role that PGRN plays in the periphery, its expression 
is of critical importance in brain health, as demonstrated by recent discovery that progranulin haploinsufficiency results in 
familial frontotemporal lobar degeneration. Since progranulin deficiency was first described, there has been an intense 
ongoing effort to decipher the mysterious role that this protein plays in dementia. This review provides an update on our 
understanding of the possible neuronal function and discusses the challenging problems related to progranulin expression 
within genetics, cell biology, and neurodegeneration.  
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INTRODUCTION 
  Progranulin (PGRN), alternatively described in the 
literature as pro-epithelin, granulin-epithelin precursor, PC-
cell-derived growth factor and acrogranin [1, 2], is a highly 
conserved, widely expressed protein that fulfills a broad 
number of roles within a diverse set of tissues, regulating the 
rapidly dividing epithelial cells of the skin, gastrointestinal 
tract, leukocytes, and the reproductive system [3]. In 
humans, PGRN transcript is expressed from the GRN gene, 
situated on chromosome 17, consisting of 13 exons that 
encode 7.5 repeats of granulin peptide motifs, including 
paragranulin and granulins A-G. The full-length PGRN 
protein is 593 amino acids long, with a predicted molecular 
mass of 63.5kDa.  
  As a secreted protein, PGRN fulfills numerous and 
complex regulatory roles in peripheral tissues. The peptide 
sequence contains an N-terminal signal directs the nascent 
protein into secretory transport; the secreted form of PGRN 
becomes glycosylated and has a molecular weight of 
approximately 90 kDa [4]. In the extracellular environment, 
PGRN can undergo cleavage by extracellular proteases 
including elastase, producing a series of 6kDa peptides [5, 
6]. These peptides are rich in cysteine residues, and can 
undergo hairpin stacking to form the secondary structures 
thought to be necessary for biological activity [7].  
  There is evidence that PGRN and the granulin cleavage 
products may have opposing effects on cell cycling and 
growth [5, 8, 9], but the precise biochemical pathways, 
including the specific receptors for these proteins, and 
interplay between these different proteins on remains largely  
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unknown. In peripheral tissues, PGRN cleavage is modulated 
by a balance of elastase and secretory leukocyte protease 
inhibitor (SLPI); SLPI can antagonize the elastase-mediated 
cleavage of PGRN [5, 6, 10]. The overall equilibrium 
between PGRN and the granulin products within the CNS, 
although currently not well-characterized, is thought to 
resemble the processes found within the periphery. 
  In the periphery, PGRN can promote tumorigenesis and 
can induce the expression of a series of inflammatory 
cytokines involved in inflammation and wound repair [1, 5, 
6, 9]. PGRN gene expression is regulated by interleukin-1 
and tumor necrosis factor-, probably through a cytokine or 
hormone binding element in the promoter region [1, 11, 12]. 
Expression data in murine embryos supports the notion that 
PGRN is involved in embryogenesis and can promote 
embryonic development of the epidermis and spermato- 
genesis, and the formation of nervous system and blood 
vessels [13]. Both PGRN and the smaller granulins have the 
capability of promoting proliferation of epithelial cells, but 
appear to differ in their capacities for doing so [3]. In support 
of these findings, sex-linked behavioral abnormalities have 
been reported in PGRN-knockout mice [14, 15].  
PGRN IN THE CENTRAL NERVOUS SYSTEM 
  During embryonic development, PGRN promotes the 
onset of blastocyst cavitation [14-17]. It is universally 
expressed in the central nervous system during early 
neuronal development, and is required for neonatal steroid-
induced sexual differentiation [13]. In rodents, PGRN is 
highly expressed in specific brain regions, including Purkinje 
cells, pyramidal and granule cells of the hippocampus,   
and the superficial lamina of cerebral cortex [3]. In 
neurologically normal patients, PGRN is similarly present in 
hippocampal pyramidal neurons, with a prominently strong Progranulin and Neurodegeneration  Current Neuropharmacology, 2011, Vol. 9, No. 4    633 
signal localized to the in CA1, dentate fascia, and endplate/ 
CA4 regions [1, 18-20].  
  The functional activities of PGRN are less well 
understood, but a similarly complex relationship is 
associated with the abilities of full length PGRN and the 
granulins in their effects on neuronal growth and survival 
[10]. In vitro, PGRN has been shown to promote growth of 
PC-12 neuronal cells from rat adrenal gland pheochro- 
mocytoma [3]. Studies of primary neurons show that full-
length PGRN and the granulin fragment GRN-E support a 
prolonged period of neuronal survival in serum and 
neurotrophin-free media [10, 21]. When added to media, 
both full length PGRN and granulins can increase axonal 
outgrowth, although this effect appears to be most 
pronounced with the full-length PGRN. The ability of PGRN 
to promote neurite growth and neuronal survival appears to 
depend on cleavage into granulins. The addition of SLPI 
ablates these effects, similar to what is seen in tumorigenesis 
[5, 10], which implies a conserved PGRN function amongst 
these different tissues.  
  It is not yet clear how granulins are produced in the 
central nervous system, but elastase and SLPI are thought to 
be produced by astrocytes and microglial cells; under these 
circumstances, a tightly-regulated network may be important 
to keep PGRN and granulins in balance [1, 22]. However, as 
our knowledge regarding the production of PGRN in the 
CNS is still rudimentary, it remains to be shown if SLPI 
works in a similar way in the central nervous system as it 
does within the periphery.  
NEUROINFLAMMATION 
  PGRN expression is known to be significantly increased 
in association with neurodegenerative disease, with much of 
this data coming from a variety of unbiased expression array 
studies. The vast majority of these studies have implied that 
PGRN is upregulated within the CNS by neuroinflammation, 
whether this is due to infection, mechanical trauma, or 
associated with neurodegenerative processes. For instance, 
PGRN expression was found to be dramatically increased in 
mice infected with the Sindbis virus in the CNS [23].  
  Microglia are the predominant immunological defense 
mechanism in the central nervous system. It is know that 
when there are insults to the CNS, such as ischemia or 
hypoxia, that result in neuroinflammation [24], prolonged 
activation of microglia is able to cause secondary neuronal 
toxicity through the generation of proinflammatory cytokines 
and reactive oxygen species [25]. Full length PGRN may 
function as an immunomodulator to suppress excess 
microglial activation; PGRN-deficient hippocampal slices 
are highly vulnerable to oxygen and glucose deprivation, and 
show increased cell death in the presence of GM-CSF and 
LPS/IFN-gamma [9]. Conditional PGRN-knockout mice also 
exhibited exaggerated inflammatory tissue damage and delayed 
recovery when exposed to bacterial lipopolysaccharide, and 
showed showing an increased density of activated microglia 
during aging, when compared to wild-type mice [9]. 
  PGRN appears to play a modulatory role in tissue 
damage within the CNS. Using a spinal cord injury mouse 
model, peak increase in PGRN mRNA and protein levels 
were observed at 7-14 days after injury, with activated 
microglia and macrophages being its main sources when 
evaluated by CD68 colocalization study [22]. The spatial and 
temporal expression of PGRN seems to be correlated with 
inflammation and recovery in this form of spinal cord 
neuronal injury. These finding parallel studies of a blunt-
force traumatic brain injury model showing increased PGRN 
mRNA levels in hippocampus at twenty-four hours, a time 
when other neurotrophic factors began or have already 
decreased to normal levels [26]. 
  Studies that have examined PGRN expression in 
neurodegenerative disorders, such as lysosomal storage 
diseases, amyotrophic lateral sclerosis (ALS), and Creutzfeldt-
Jakob disease, show similar degrees of upregulation [1]. 
Compared with unaffected tissues in normal patients, in 
these disorders PGRN expression is prominently located in 
activated microglia [2, 18, 20]. In studies of Alzheimer’s 
disease, several reports have shown increased PGRN 
immunoreactivity is associated with amyloid plaques Fig. 
(1), dystrophic neurites, and microglia [27-29]. From these 
studies, it is not entirely clear whether PGRN is purely 
intracellular or is secreted and extracellularly associated with 
plaques; nevertheless, based upon previous observations, a 
substantial quantity of PGRN is likely to be contributed by 
activated microglia.  
  While these studies add to our knowledge about the 
dynamic nature of PGRN expression in disease, more 
experiments are needed to establish the definitively establish 
to part that PGRN plays in modulating neuroinflammation. 
The appropriate expression of PGRN in a timely manner 
might be important in maintenance of brain functions. 
However, little is known about the mechanisms under which 
PGRN becomes upregulated in microglia under such 
conditions, and it remains unclear if this protein will be 
beneficial or detrimental once it becomes over-expressed in 









Fig. (1). Immunofluorescence image from the hippocampus of a 15 
month-old Tg2576 mouse model of Alzheimer’s disease, showing 
PGRN staining. A majority of amyloid plaques (indicated here by *) 
display intensely immunoreactivity for PGRN. Key: Green, PGRN; 
Red, glial fibrillary acidic protein; Blue , DAPI. 634    Current Neuropharmacology, 2011, Vol. 9, No. 4  Sun
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increased expression of PGRN might be an effort to 
compensate and to rescue the neuronal functions as shown 
by its neurotrophic role in primary culture, it is possible that 
PGRN may exert a detrimental influence on the CNS, 
resulting in neuronal injury, especially if this protein is 
overexpressed on a long-term basis.  
FRONTOTEMPORAL DEMENTIA 
  Patients diagnosed with frontotemporal dementia (FTD; 
alternatively identified as FTLD, frontemporal lobar 
degeneration) experience a prominent loss of language, 
significant changes of personality, and early alterations of 
social interactions and behaviors, characterized by the 
atrophy of the frontal and temporal lobes, with the relative 
sparing of the occipital and parietal lobes, sparing visual and 
spatial functions [30]. Familial forms of FTD account for the 
majority of all FTD cases, typically with an autosomal 
dominant inheritance pattern. Nevertheless, while many 
forms of FTLD display similar symptoms and are classified 
as early-onset dementias, this disorder can be subdivided into 
a set of disease entities with differences in clinical and 
pathological manifestations. 
  Clinically, FTLD patients may differ in their major 
symptoms, age of onset, and the course of the disease. 
Neuropathologically, FTLD can be divided into four 
subtypes according to its histology (Table 1); this includes 
FTLD with tau deposits, FLTD with tau-negative, ubiquitin 
and TDP-43 positive inclusions (now called FTLD-TDP), 
and FTLD with neuronal intermediate filament inclusions 
(NIFID), and cases with no detectable inclusions [31]. The 
latter two subtypes have been combined into one group, 
FTLD-FUS, as FUS immunoreactivity is the uniform 
characteristic in these inclusions [32].  
  Four genes are currently associated with FTLD, 
including  MAPT (microtubule-associated tau protein) on 
chromosome 17q21.32 [33-35], VCP (Valosin-containing 
protein) on chromosome 9p13.3 [36], CHMP2B (Chromatin 
modifying protein 2B ) on chromosome 3p11.2 [37], and 
GRN (PGRN) on chromosome 17q21.32 [20, 38, 39]. MAPT 
and GRN mutations are the most common forms of FTLD 
disease, with around 10-20% of familial FTLD patients with 
MAPT mutations, and a similar number of GRN  mutation 
carriers [32]. MAPT mutations typically affect tau splicing at 
the mRNA level, or alter binding activity with microtubules 
but these mutations typically have little influence on total   
tau protein levels. In contrast, mutations in GRN play a 
predominant role in the development of FTLD pathology 
containing ubiquitinated, TDP-43-positive inclusions [39, 
40]. The vast majority of GRN mutations that have been 
identified to the present cause a loss-of-function and 
decreased levels of PGRN expression through the introduc- 
tion of a premature stop codon [41, 42]. 
  The major neuropathology distinguishing FTLD 
associated with GRN mutations, from those without GRN 
mutations of PGRN is the presence of ubiquitin-positive 
lentiform neuronal intranuclear inclusions in the neocortex 
and striatum [2, 18, 39]. Other less significant characteristics 
include superficial laminar spongiosis, chronic neuronal de- 
generation, ubiquitin-immunoreactive neurites and ubiquitin-
immunoreactive neuronal cytoplasmic inclusions. In these 
patients, ubiquitin-immunoreactive neurites are mostly seen 
in the striatum, and neuronal cytoplasmic inclusions in the 
hippocampus are usually present in a granular pattern. In 
contrast, no neuronal intranuclear inclusions are found in 
familial FTLD in patients lacking GRN  mutations, along 
with less severe neocortical and striatal pathology. Patients 
Table 1.  2010 Recommendations by Mackenzie [89] for Classification of FTLD Subtypes. The Subtype Indicates A Characteristic 
Pattern of Underlying Pathology, Rather than Clinical Syndrome Displayed by the Patient  
Major Class  Subtype  Associated Gene 
Pick’s disease  MAPT 
Corticobasal degeneration   
Progressive supranuclear palsy   
Argyrophilic grain disease   
Multiple system tauopathy with dementia   
Neurofibrillary tangle predominant dementia   
White matter tauopathy with globular glial inclusions   
FLTD-tau 
Unclassifiable  
Types 1-4  GRN  FTLD-TDP 
Unclassifiable 9p  (TARDBP) 
FTLD-UPS  FTD-3  CHMP2B 
Atypical frontotemporal lobar degeneration with ubiquitinated inclusions  FUS 
Neuronal intermediate filament inclusion disease   
FTLD-FUS 
Basophilic inclusion body disease   
FTLD-ni  No inclusions   Progranulin and Neurodegeneration  Current Neuropharmacology, 2011, Vol. 9, No. 4    635 
diagnosed with FTLD-TDP demonstrate that PGRN 
immunoreactivity is most intensely found in activated 
microglia; PGRN so far has not been directly associated with 
ubiquitin-immunoreactive inclusions [1, 39].  
The Identification and Impact of GRN Mutations  
  Since the first genetic linkage study identified the 
existence of MAPT gene mutations with familial FTLD [33-
35], a significant amount of effort has been invested into the 
identification of novel genes associated with frontotemporal 
dementia, the second most common cause of senile 
dementia. Although several groups had reported an exclusive 
presence of tau-negative, ubiquitin-positive neuronal 
intranuclear inclusions in a subset of familial FTD patients 
without identifiable MAPT mutations, and others had 
narrowed potential candidate region to an area surrounding 
the MAPT [43-45], it was not until 2006 that GRN mutations 
were identified in familial FTLD via extensive candidate-
gene sequencing [20, 39, 46]. Mutations in this gene were 
difficult to identify in part because it was 1.7 Mb proximal to 
the  MAPT gene, a significant challenge for traditional 
genetic analysis.  
  The seminal discovery of PGRN mutations in familial 
FTD resulted in a flurry of subsequent genetic screens and 
identification of novel familial mutations, expanding our 
understanding of the prevalence of GRN mutations and 
mechanisms of action in neurodegeneration. Currently, 68 
PGRN mutations have been identified in 212 families 
(http://www.molgen.ua.ac.be/FTDMutations), including small 
insertions and deletions leading to a variety of frame-shift, 
nonsense, splice-site, and missense mutations (see reviews 
[41, 47, 48]); large-scale or complete deletion of GRN has 
been reported in several rare cases [47, 49]. These mutations 
have a common effect of reducing constitutive PGRN levels, 
but the underlying mechanisms through which this process 
occurs is likely to be different in some cases. Splice-site 
mutations may prevent the export of PGRN, subjecting 
PGRN to degradation [50]; in contrast, the most well-known 
of these is the haploinsufficiency mechanism; the introduc- 
tion of premature stop codon results in nonsense-mediated 
RNA decay and a loss of 50 percent functional PGRN   
[20, 38, 48]. In addition to these mechanisms, less common 
mutations associated with a signal peptide motif appear to 
reduce PGRN expression by affecting the localization and 
secretion of the protein [19, 31, 51]. 
  Based on the hypothesis that haploinsufficiency is a key 
contributor to neurodegeneration observed in FTLD-TDP, 
protein expression of PGRN in brain should, theoretically, 
always be reduced. However, in recent work [52] examining 
brain PGRN expression in FTLD-TDP patients with 
(PGRN+ FTLD-TDP) and without (PGRN- FTLD-TDP) 
GRN mutations, PGRN mRNA levels were surprisingly 
much higher in the most heavily affected brain region-frontal 
lobe in PGRN+ FTLD-TDP compared to those in PGRN- 
FTLD-TDP and neuropathologically-normal patients, while 
no significant differences were found in the other areas. 
Allele analysis indicated that the increased PGRN mRNA 
level came from the normal allele. Subsequent immuno- 
histochemistry staining suggested a prominent infiltration of 
microglia in frontal lobes, which might be the culprit serving 
increased PGRN mRNA levels in this condition. Protein 
levels remained lower for GRN mutation carriers in all four 
brain regions despite large variations among individuals in 
PGRN+ FTLD-TDP, potentially due to possible post-
transcriptional modifications or failure of detection of full-
length PGRN in ELISA. While the study points towards a 
role of microglial PGRN correlated with PGRN+ FTLD-
TDP, the exact mechanism as to how this occurs is 
undetermined; additional patients will be needed to expand 
and confirm the distribution pattern of PGRN in FTLD-TDP 
associated with PGRN mutations. Comparative functional 
studies in different cell populations will be needed to address 
if there are two separate pools of PGRN in neurons and 
microglia cells within the CNS.  
PGRN and TDP-43 in FTLD  
  Widely expressed and predominantly nuclear, TDP-43 is 
a protein with 441 amino acids that is encoded by TARDBP 
gene on chromosome 1. It contains two RNA-recognition 
motifs and a C-terminal glycine-rich region that may mediate 
interactions with other proteins. It is a pleiotropic protein 
implicated in the regulation of gene expression including 
transcription, RNA splicing and transport, and translation 
[53, 54] and in maintenance of cell survival [55]. Apart from 
its role in gene regulation, other functions of this protein 
were largely unknown. However, in late 2006, Aria [56] and 
Neumann [57] independently reported that the heavily 
ubiquitinated inclusions in the brains of FTLD-TDP and 
amyloid lateral sclerosis (ALS) patients were predominantly 
composed of abnormally hyperphosphorylated and 
ubiquitinated TDP-43 protein, indicating a possible common 
pathogenic mechanism. As GRN mutation carriers invariably 
develop TDP-43 positive inclusions, these studies propelled 
the development of studies to assess the relationship between 
PGRN expression and TDP-43 patholog [20, 38]. Since   
the initial publication of these findings, a large number   
of  GRN mutation variants have been identified in FTLD-
TDP families across the world, strongly supporting the 
relationship between PGRN expression and the development 
TDP-43 pathology [32].  
  It is interesting to note that reduced levels of PGRN are 
also highly associated with the development of TDP-43-
positive pathology in Alzheimer’s disease in the form of 
hippocampal sclerosis [58, 59]. Since the majority of GRN 
mutations have been reported to create null alleles, resulting 
in reduced protein levels, it is suspected that the protein 
might be a potential neurotrophic factor whose loss of 
function may justify the underlying mechanisms of neuro- 
degeneration in FTLD-TDP or other related diseases [1].   
In fact, little immunoreactivity of PGRN was detectable   
in degenerating neurons, consistent with the consequence   
via haploinsufficiency mechanism [39]. 
  Although the initial discovery of aggregated TDP-43 
inclusions represented a tremendous advance in the field, 
these studies did not show if TDP-43 pathology was merely 
a byproduct of other pathogenic progress, or was a casual 636    Current Neuropharmacology, 2011, Vol. 9, No. 4  Sun
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factor resulting in neurodegeneration. The following year 
after TDP-43 aggregates were described in ALS and FTLD-
TDP, dominant mutations in the TARDBP gene were 
reported by several groups as a primary cause of ALS in a 
variety of populations [42, 60-62]. These studies collectively 
provided evidence that the aberrant form of TDP-43 can 
directly trigger neurodegeneration. To date, 29 TARBP 
missense mutations have been reported excluding those 
benign gene variants, with all but one localized in the C-
terminal glycine-rich region [60, 61, 63].  
  Cluster mutations in the highly conserved c-terminal 
region of TDP-43 identified in ALS may affect its 
transportation through the nuclear pore by interfering with 
the normal protein-protein interactions [60, 61]. All 
TARDBP mutations exhibit an autosomal dominant pattern 
of inheritance, and are almost exclusively seen in ALS. Most 
recently, two patients with FTLD plus motor neuron diseases 
(FTLD-MND) bearing a TARDBP mutation were also 
reported [64], illustrating that the pathogenic mutations, 
although rare, are not limited to ALS. While the studies of 
mutations in TARDBP have provided a number of powerful 
observations, it was unclear whether TDP-43 mutations 
caused neuronal death through a loss of normal function or 
through a gain-of-toxic function.  
  Studies using different models suggest both pathways 
may potentially be important. Normally, TDP-43 shuttles 
between the nuclear and the cytoplasm exerting its biological 
functions in a transcription-dependent manner. The C-
terminus is closely related to the solubility of the protein 
[55]; mutant forms of TDP-43 bearing the Q331K are more 
prone to aggregation [65]. Using in vitro cell models, TDP-
43 Q331K or M337V missense mutations were shown to be 
associated with embryonic growth defects via pro-apoptotic 
effect in a chicken embryo model [61], suggesting a potential 
toxic gain of function. In support of the loss of function 
hypothesis, Drosphila lacking TDBH, the TDP-43 homolog 
protein, exhibits motor defects and abnormal synaptic 
terminals, a phenotype that can be rescued by human TDP-
43 or TDBH expression [66].  
  While these observations provide significant insights into 
the genetics and cell biology of TDP-43, the relationship of 
TDP-43 and PGRN is still not well-characterized. In cell 
studies, PGRN knockdown leads to a caspase-3 dependent 
degradation of TDP-43, generating two fragments with the 
apparent molecular weight of 25kDa and 35kDa, respectively 
[67]. These findings suggest a possible mechanism of PGRN 
insufficiency and neurodegeneration through the production 
of generating toxic fragments of TDP-43. Indeed, the 25kDa 
fragment is able to induce cell toxicity via  formation  
of insoluble, hyperphosphorylated and ubiquitin-positive 
inclusions in the cytosol of H4 cells, consistent with what is 
seen in FTLD-TDP inclusions [68]. Unfortunately, no data 
was shown if PGRN overexpression could rescue the 
degradation observed in these cell models [67]. 
  In addition to TDP-43, FUS/TLS, another DNA/RNA 
binding protein, was recently identified as a causative gene 
in a subset of ALS [69, 70]; increased FUS immuno- 
reactivity in FTLD subtypes constitute a new group that 
combines the neuropathology with undefined histology and 
with intermediate neurofilament inclusions [32]. No FUS 
mutations or variability have been identified in FTLD as far. 
Considering similar roles of FUS and TDP-43 involved in 
gene regulation, it might be reasonable to suspect that 
dysfunction of RNA metabolism, suggestive of a loss-of-
function model, might be the common pathway leading to 
neurodegeneration, regardless of the initial etiology or 
genetic heterogeneity [54].  
  Attempts to model the association between PGRN and 
TDP-43 using transgenic mice have so far only partially 
recapitulated the neurodegenerative phenotype observed in 
humans, suggesting that there are some key underlying 
functional differences between mouse models and in FTLD-
TDP patients that are not currently understood. None of the 
PGRN mouse lines that have been developed so far, either as 
partial or complete knockouts, show the severe and 
progressive neurodegenerative phenotype that is associated 
with FTLD-TDP patients. The transgenic mouse models, 
however, do appear to show some signs of dysfunction.   
One of the earliest characterized PGRN KO mouse lines 
displayed alterations in neuroinflammation, focal neuronal 
loss, and the development of ubiquitin-positive lipofuscin 
during aging, but without clear changes in TDP-43 
localization or distribution [71]. In contrast, another mouse 
model of PGRN was reported to have altered distribution of 
TDP-43 from nucleus to cytoplasm in hippocampal and 
thalamus; there was some disruption in learning and memory 
tests, although without clear evidence for cerebral atrophy 
[9, 72].  
Modifiers of PGRN Expression 
  Although mutations in GRN are correlated with the 
development of several well-characterized subtypes of FTLD 
neuropathology, genetic studies of families with GRN 
mutations have shown that there is substantial variability of 
clinical phenotypes in the aspect of age of onset, disease 
duration, severity and detailed manifestations [48]. The 
clinical heterogeneity suggests that there might be additional 
gene and environmental factors that can modify the 
progression of the disease. Indeed, several single nucleotide 
polymorphisms (SNPs) have been reported to be associated 
with sporadic FTLD without causal GRN mutations. The 
neuronal nitric oxide synthase (NOS) C276T polymorphism 
is associated with a substantially greater risk of developing 
FTLD (OR=1.96, 95% CI: 1.11-3.47) in a small Italian 
cohort (n=71 for cases) [73]. In another study, (n=222), the 
authors found that the endothelial NOS G893T polymorphism 
might increase the risk of FTLD by 65% [74], and the GG 
genotype of rs4859146 SNP in defective in cullin neddylation 
1 (DCN-1)-domain containing 1 (DCUN1D1), involved in 
protein degradation, increased the risk more than 3-fold [75]. 
While the findings above suggested that the pathways of 
oxidative stress and protein degradation might be involved in 
FTLD, the results should be treated with caution as these 
studies used only clinically diagnosed FTLD patients in a 
single population; the possibility of false association cannot 
be excluded unless confirmed by larger studies in different 
populations. The neuropathology of FTLD patients and 
controls was also not available and could represent a mixture 
of different subtypes. Progranulin and Neurodegeneration  Current Neuropharmacology, 2011, Vol. 9, No. 4    637 
  In a series of pathologically-confirmed FTLD patients 
without  GRN mutations, Rademakers and colleagues 
demonstrated that a common genetic variant (rs5848) in a 
binding-site for microRNA miR-659, located in the 3'-
untranslated region (UTR) of PGRN, was a major 
susceptibility factor for FTLD-TDP [42]. TT genotype of 
rs5848 increased the risk to develop FTLD-TDP by around 3 
fold compared with CC genotype (95% CI: 1.50-6.73; n=339 
for cases and n=934 for controls); PGRN levels were 
significantly reduced in TT homozygotes [42]. miR-659 
appears to confer an increased risk for FTLD-TDP through 
an inhibition of PGRN translation, generating an effect 
resembling the biochemistry and pathology observed in 
PGRN- null mutations. This association was independently 
confirmed by another group showing that the rs5848 TT 
genotype resulted in a decrease in GRN mRNA levels over 
the CC genotype. A recent follow-up study examined the 
serum of patients with the rs5848 genotype [76], and showed 
that patients in the CC subgroup displayed the highest level 
of serum PGRN, CT group had intermediate values, and the 
TT group had the lowest level. Although this study utilized a 
small cohort of subjects, it appears to confirm the biological 
association between variations in R5848 and PGRN levels. It 
should be noted that two groups reported that they were 
unable to replicate the effect of the rs5848 polymorphism 
[77, 78]. The discrepancy might be due to several possible 
reasons such as a relatively weak or modifiable effect of the 
T allele, a smaller percentage or specific differences in the 
neuropathology of FTLD-TDP cohorts.  
  In addition to miR-659, a genome-wide association   
study identified three single nucleotide polymorphisms at 
chromosome 7p21 [79], involving 545 cases of neuro- 
pathologically-confirmed FTLD-TDP patients. The corres- 
ponding region includes TMEM106B, a gene encoding an 
unrecognized transmembrane protein with 274 amino acids, 
with a preferable expression in the frontal lobe. The mRNA 
levels are significantly higher in FTLD-TDP patients compared 
to controls and in FTLD-TDP with GRN mutations, compared 
to non-carriers. Analysis of the heterozygotes on SNP site 
rs1990622 showed that the presence of PGRN mutation 
remains associated with increased TMEM106B expression, 
indicating that the TMEM106B genotype is not only a 
genetic risk factor for overall FTLD, but may probably 
confer additional risk for PGRN mutation carriers. In follow-
up studies, an association analysis demonstrated a highly 
significant correlation between TMEM106B and PGRN 
plasma levels and mRNA expression, with greater statistical 
significance in patients with FTLD with GRN  mutations 
[80]; these results suggested that TMEM106B expression 
modulates the development of FTLD through its interactions 
with PGRN. This protein appears to interact with PGRN to 
influence its activity in FTLD-TDP, although the function of 
TMEM106B remains poorly understood. 
Prognostic Biomarkers for FTLD-TDP 
  As most of the GRN variants associated with FTLD-TDP 
are null mutations, additional efforts have been directed 
towards developing methods, other than genetic analysis, for 
early diagnosis of the disease, especially in patients with 
atypical symptoms. Since the first report that mRNA levels 
in blood cells were significantly reduced in PGRN mutation 
carriers by approximately 35% [81], PGRN is decreased in 
plasma [82], serum [83], and cerebral spinal fluid in FTLD 
patients bearing the PGRN mutations but remains unchanged 
in those without PGRN mutations or normal patients.   
Finch and colleagues [84] reported that the plasma levels of 
full-length PGRN were significantly decreased in both 
symptomatic and asymptomatic PGRN mutation carriers, 
compared to relatives without PGRN mutations. Although 
this observation needs to be confirmed in additional FTLD 
families, these findings offer the promise that plasma PGRN 
levels might be used as a screening tool to predict the PGRN 
mutation status especially in those asymptomatic members of 
the family, which is valuable for evaluation of possible 
preventive care.  
  While PGRN is a secreted protein that can be readily 
detected in plasma, it is somewhat surprising that TDP-43, a 
predominantly nuclear protein, is also detectable in plasma 
with ELISA [85]; raised levels of TDP-43 were detected in 
46% of FTLD patients, 22% of Alzheimer’s disease and 8% 
of controls. In studies of ALS patients in a Japanese 
population, elevated levels of TDP-43 in the cerebral spinal 
fluid suggested this diagnostic may be of value at the early 
stages of disease [86]. Consequently, plasma levels of TDP-
43 protein may also be of value in diagnosing FTLD patients 
with TDP-43 inclusions. Nevertheless, it is important to   
not out that diagnosis of the disease is purely correlative at 
this point. In order to judge the utility of this approach, a 
larger cohort of patients with neuropathologically confirmed 
diagnoses will be needed to verify if TDP-43 levels in blood 
plasma indeed appropriately correlate with TDP-43 pathology 
in the brain.  
THERAPEUTIC APPROACHES TO PGRN HAPLO- 
INSUFFICIENCY 
  Although the role that PGRN plays in the nervous system 
is as yet largely undefined, two groups, complimentary 
approaches of genetic and functional screening recently 
independently reported Sortilin (SORT1) as a high affinity 
neuronal receptor for PGRN [87, 88]. Sortilin is a member of 
the cellular Vps10 key type I receptor, which is expressed 
largely on neurons, and this receptor binds a number of 
different ligands, including the neuropeptide neurotensin and 
pro-NGF.  
  In studies of the functional interaction between sortilin 
and PGRN, mice lacking the sortilin receptor had elevated 
levels of serum and brain PGRN, indicating that sortilin 
functions an important endogenous regulator of PGRN 
levels; however, overexpression of PGRN did not affect 
sortilin levels. As shown in Fig. (2), follow-up studies 
showed that PGRN was targeted to the endosomal-lysosomal 
pathway in neurons, suggesting that this protein plays a 
potentially important role in the degradation of proteins, but 
the precise function of this protein within the lysosome as 
yet remains undefined [87]. Although much work remains to 
be done to define the role of PGRN within the nervous 
system, these recent discoveries suggest that medications 
that targeting the sortilin receptor may be of significant 
utility in treating FTLD-TDP. 638    Current Neuropharmacology, 2011, Vol. 9, No. 4  Sun
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CONCLUDING REMARKS 
  Despite many studies that have demonstrated the impact 
of  GRN haploinsufficiency on brain health, our under- 
standing of the functional role of PGRN and its relationship 
to neurodegeneration is still nascent. Functional studies 
suggest that this protein has pleiotropic activities, fulling 
roles as both a full-length protein and in the form of protein 
fragments. In studies of peripheral tissues, PGRN exerts an 
impact on development, inflammation, tissue repair and 
oncogenesis. There appear to be strong parallels between the 
periphery  and CNS in the regulation of this protein by 
inflammation within the microglial population, but the func- 
tion of PGRN within neurons, and its relationship to TDP-43 
expression, remains much less understood. Although it has 
been commonly believed that a simple reduction in PGRN 
levels will result in neurodegeneration, this assumption has 
been challenged by recent work showing high levels of 
PGRN expression in FTLD-TDP patient population, and 
raises the question of whether PGRN produced by the two 
subpopulations of neurons and microglia fulfills an identical 
function in both cell types. If the role of PGRN is identical 
between neurons and microglia, this would argue that any 
increase in PGRN would be sufficient to rescue PGRN 
haploinsufficiency, whether this comes from a neuronal or 
microglia population. However, in most diseases it appears 
likely, although has not been entirely proven, that most of 
the PGRN is provided by activated microglia caused by 
neuronal inflammatory events. Future studies to dissect the 
differences in function in the neuronal and microglial 
populations, both in health and disease, and the relationship 
of this expression to TDP-43, will prove to be very 
informative in elucidating the function of this protein and its 
role in neurodegeneration. 
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